JP2022551270A5 - - Google Patents
Info
- Publication number
- JP2022551270A5 JP2022551270A5 JP2022520475A JP2022520475A JP2022551270A5 JP 2022551270 A5 JP2022551270 A5 JP 2022551270A5 JP 2022520475 A JP2022520475 A JP 2022520475A JP 2022520475 A JP2022520475 A JP 2022520475A JP 2022551270 A5 JP2022551270 A5 JP 2022551270A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- stereoisomers
- independently
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025113088A JP2025164962A (ja) | 2019-10-04 | 2025-07-03 | ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962911069P | 2019-10-04 | 2019-10-04 | |
| US62/911,069 | 2019-10-04 | ||
| US202062991525P | 2020-03-18 | 2020-03-18 | |
| US62/991,525 | 2020-03-18 | ||
| PCT/US2020/054107 WO2021067836A1 (en) | 2019-10-04 | 2020-10-02 | Chinone-, hydrochinome- and naphthochinone-analogues of vatiquione for treatment of mitochondrial disorder diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025113088A Division JP2025164962A (ja) | 2019-10-04 | 2025-07-03 | ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022551270A JP2022551270A (ja) | 2022-12-08 |
| JP2022551270A5 true JP2022551270A5 (cg-RX-API-DMAC10.html) | 2024-03-28 |
Family
ID=72964859
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022520475A Pending JP2022551270A (ja) | 2019-10-04 | 2020-10-02 | ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体 |
| JP2025113088A Pending JP2025164962A (ja) | 2019-10-04 | 2025-07-03 | ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025113088A Pending JP2025164962A (ja) | 2019-10-04 | 2025-07-03 | ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US11584728B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4038076A1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP2022551270A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20220078644A (cg-RX-API-DMAC10.html) |
| CN (2) | CN114746430B (cg-RX-API-DMAC10.html) |
| AU (2) | AU2020358970C1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3156499A1 (cg-RX-API-DMAC10.html) |
| IL (2) | IL291898B1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021067836A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL291898B1 (en) * | 2019-10-04 | 2026-06-01 | Stealth Biotherapeutics Inc | Quinone-, hydroquinone-, and naphthoquinone- analogs of quinone for the treatment of mitochondrial disorders |
| AU2022291142A1 (en) * | 2021-06-10 | 2023-12-21 | Stealth Biotherapeutics Inc. | Compounds, compositions and methods for the prevention and/or treatment of various mitochondrial diseases or disorders, including friedreich's ataxia |
| US11541116B1 (en) | 2022-01-07 | 2023-01-03 | Kojin Therapeutics, Inc. | Methods and compositions for inducing ferroptosis in vivo |
| AU2024300048A1 (en) * | 2023-07-21 | 2026-01-22 | Stealth Biotherapeutics Inc. | Methods, compositions and uses related to the treatment and prevention of leigh's syndrome |
| AU2024377199A1 (en) * | 2023-11-09 | 2026-05-21 | Stealth Biotherapeutics Inc. | Cyclo-hexa-2,5-diene-1,4-diones for use in the treatment of cardiomyopathy |
| WO2025231245A1 (en) * | 2024-05-02 | 2025-11-06 | Stealth Biotherapeutics Inc. | Use of substituted 1,4 benzoquinones to treat alpha-synucleinopathies |
| WO2026020091A1 (en) * | 2024-07-19 | 2026-01-22 | Stealth Biotherapeutics Inc. | Methods, compounds, compositions, formulations and uses for addressing mitochondrial disease resulting from nuclear dna mutations |
| WO2026050137A1 (en) * | 2024-08-26 | 2026-03-05 | Stealth Biotherapeutics Inc. | A combination therapy for the treatment of friedreich's ataxia |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JP3507486B2 (ja) | 1991-03-15 | 2004-03-15 | アムジエン・インコーポレーテツド | 顆粒球コロニー刺激因子の肺内投与 |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| CA2272971C (en) | 1998-10-29 | 2008-01-15 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Quinone derivatives for treating or preventing diseases associated with iron overload |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| WO2005033092A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | Chroman derivatives |
| EA035619B1 (ru) * | 2005-06-01 | 2020-07-16 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Композиции для использования в способе лечения митохондриальных нарушений |
| JP2009508867A (ja) | 2005-09-15 | 2009-03-05 | エジソン ファーマシューティカルズ, インコーポレイテッド | ミトコンドリア病および関連した様態の治療ならびにエネルギーバイオマーカーの調節のための酸化還元活性治療剤のテイル改変体 |
| EP2332534B1 (en) * | 2006-02-22 | 2018-11-14 | Bioelectron Technology Corporation | Phenol and benzoquinone derivatives for use in the treatment of mitochondrial diseases and modulation of energy biomarkers |
| EP1986636B1 (en) | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
| WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| EP2303824B1 (en) | 2008-06-25 | 2015-03-25 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| EP2344142B1 (en) | 2008-09-10 | 2024-06-26 | PTC Therapeutics, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| WO2010051277A1 (en) | 2008-10-28 | 2010-05-06 | Edison Pharmaceuticals, Inc. | Process for the production of alpha-tocotrienol and derivatives |
| EP2246048A1 (en) | 2009-04-30 | 2010-11-03 | Santhera Pharmaceuticals (Schweiz) AG | Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis |
| NO2470168T3 (cg-RX-API-DMAC10.html) | 2009-08-26 | 2018-06-30 | ||
| US20130345312A1 (en) | 2010-08-06 | 2013-12-26 | Orion D. Jankowski | Treatment of mitochondrial diseases with naphthoquinones |
| EP2606022A2 (en) * | 2010-08-16 | 2013-06-26 | Santhera Pharmaceuticals (Schweiz) AG | Novel benzoquinone derivatives and use thereof as modulators of mitochondrial function |
| HRP20161407T1 (hr) | 2010-08-16 | 2016-12-02 | Santhera Pharmaceuticals (Schweiz) Ag | Derivati benzokinona za liječenje mitohondrijskih bolesti oka |
| WO2012068552A1 (en) | 2010-11-19 | 2012-05-24 | Edison Pharmaceuticals, Inc. | Methods for improving blood glucose control |
| WO2012170773A1 (en) | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones |
| KR102137450B1 (ko) * | 2012-07-12 | 2020-07-27 | 콘드리온 아이피 비.브이. | 미토콘드리아 질환을 치료하기 위한 크로마닐 유도체 |
| CA2883879A1 (en) | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Quinone derivatives for use in the modulation of redox status of individuals |
| JP6367211B2 (ja) | 2012-11-16 | 2018-08-01 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | リソソーム蓄積症の改善物質としてのトコフェロール誘導体およびトコフェリルキノン誘導体 |
| JP2016515526A (ja) * | 2013-03-15 | 2016-05-30 | エジソン ファーマシューティカルズ, インコーポレイテッド | 酸化ストレス障害の処置のためのアルキル−ヘテロアリール置換されたキノン誘導体 |
| WO2015183963A2 (en) | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including redox-active parabenzoquinones and uses thereof |
| EP3377179B1 (en) | 2015-11-19 | 2021-04-07 | Concert Pharmaceuticals Inc. | Deuterated epi-743 |
| EP3389646A1 (en) | 2015-12-17 | 2018-10-24 | BioElectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| CA3011293A1 (en) | 2016-01-12 | 2017-07-20 | Ptc Therapeutics, Inc. | Tocopherol and tocotrienol quinone derivatives for increasing thiosulfate levels or decreasing hydrogen sulfide levels |
| WO2018191732A1 (en) | 2017-04-14 | 2018-10-18 | Bioelectron Technology Corporation | Methods and compositions for treatment of inflammation and oxidative stress |
| JP7266304B2 (ja) | 2017-04-21 | 2023-04-28 | ユニヴァーシティー オブ タスマニア | 治療化合物および方法 |
| IL305687B2 (en) | 2017-12-15 | 2024-12-01 | Stealth Biotherapeutics Inc | Mitochondria-targeting peptides |
| IL291898B1 (en) * | 2019-10-04 | 2026-06-01 | Stealth Biotherapeutics Inc | Quinone-, hydroquinone-, and naphthoquinone- analogs of quinone for the treatment of mitochondrial disorders |
-
2020
- 2020-10-01 IL IL291898A patent/IL291898B1/en unknown
- 2020-10-02 IL IL328635A patent/IL328635A/en unknown
- 2020-10-02 JP JP2022520475A patent/JP2022551270A/ja active Pending
- 2020-10-02 US US17/062,339 patent/US11584728B2/en active Active
- 2020-10-02 CN CN202080084283.6A patent/CN114746430B/zh active Active
- 2020-10-02 EP EP20793924.0A patent/EP4038076A1/en active Pending
- 2020-10-02 CN CN202610035916.3A patent/CN121949079A/zh active Pending
- 2020-10-02 WO PCT/US2020/054107 patent/WO2021067836A1/en not_active Ceased
- 2020-10-02 CA CA3156499A patent/CA3156499A1/en active Pending
- 2020-10-02 AU AU2020358970A patent/AU2020358970C1/en active Active
- 2020-10-02 KR KR1020227014887A patent/KR20220078644A/ko active Pending
-
2022
- 2022-12-23 US US18/087,890 patent/US12049455B2/en active Active
-
2024
- 2024-07-02 US US18/761,854 patent/US20240400529A1/en active Pending
- 2024-07-02 US US18/761,782 patent/US20240368098A1/en active Pending
-
2025
- 2025-07-03 JP JP2025113088A patent/JP2025164962A/ja active Pending
-
2026
- 2026-05-02 AU AU2026203365A patent/AU2026203365A1/en active Pending